For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39273 Lyra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) ...

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Stephanie Marks - Investor Relations, Argot Partners Maria Palasis - President & Chief Executive Officer Robert Kern - Chief Medical Officer Don Elsey - Chief Financial Officer Corinne Noyes - Senior Vice President, Commercial Strategy & Market Development Conference Call Participants Bert Hazlett - BTIG Tim Lugo - William Blair Ashwani Verma - Bank of America Operator Welcome to the Lyra Th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39273 Lyra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (Stat ...

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Q1 2021 Earnings Conference Call May 11, 2021 4:30 PM ET Company Participants Stephen Jasper - Principal, Gilmartin Group Maria Palasis - President and Chief Executive Officer Rob Kern - Chief Medical Officer Don Elsey - Chief Financial Officer Conference Call Participants Perry Mayo-Malasky - BTIG Jason Gerberry - Bank of America Chris Howerton - Jefferies Operator Welcome to the Lyra Therapeutics First Quarter 2021 Financial Results and Corporate Update Conference Ca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39273 Lyra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (Sta ...

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Q4 2020 Earnings Conference Call March 9, 2021 4:30 PM ET Company Participants Laurence Watts - Managing Director, Gilmartin Group Maria Palasis - President & Chief Executive Officer Rob Kern - Chief Medical Officer Don Elsey - Chief Financial Officer Corinne Noyes - Senior Vice President of Commercial Strategy & Market Development Conference Call Participants Chris Howerton - Jefferies Bert Hazlett - BTIG Ash Verma - Bank of America Tim Lugo - William Blair Operator We ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39273 Lyra Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39273 Lyra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) ...

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants Laurence Watts - Managing Director Gilmartin Group Maria Palasis - President and Chief Executive Officer Don Elsey - Chief Financial Officer Corinne Noyes - Senior Vice President of Commercial Strategy and Market Development Conference Call Participants Ashwani Verma - Bank of America Chris Howerton - Jeffries Robert Hazlett - BTIG Operator Welcome to the Lyra Therapeutics Second Quarter 20 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39273 Lyra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (Stat ...